An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

Also called NCT07923526

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07923526
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07923526. Allocation not applicable; no masking; primary purpose treatment. Start 2027-03 (anticipated); primary completion 2034-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Acronym
SUMMIT OLE
Condition
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Intervention (Combination product)
treprostinil SMI (treprostinil inhalation spray)
Lead sponsor
United Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct07923526
Content hash
bcbec09bd9271e50a30d1449f347b330fca385c582e2958dfd6bf3ec3efa7755